Drug news
NICE widens scope of guidance fro Xofigo (radium Ra 223 dichloride)to apply to prostate patients unsuitable for chemotherapy.- Bayer HealthCare
The National Institute for Health and Care Excellence has in final draft guidance widened the scope of Xofigo (radium Ra 223 dichloride) from Bayer HealthCare to enable prostate patients unsuitable for chemotherapy treatment such as Taxotere (docetaxel) to be treated with the drug. Formerly these patients had access to the drug for this indication through the Cancer Drugs Fund.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.